Emmanuel Antonarakis, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Amgen
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    QIAGEN
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Dendreon
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Clovis
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    ESSA
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Sanofi
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    11/09/2023

Pages

Return to PARP Inhibitors: Assessing the Clinical Trial Landscape Webcast (2021)